The United States of America As Represented by the Department of Health

McClellan M Walther

Paul D Smith

Walter S Friauf

Frank S Harrington

Thomas F DeLaney

Charles E Myers

Cy A Stein

Renato V LaRocca

W Marston Linehan

An obturator for measuring incident light in a remote situs such as a body cavity which includes a treatment tubular member through which light is delivered to the remote situs and one or more auxiliary tubular members through which incident light in the remote situs is transmitted to an external light detector. The treatment and auxiliary tubular members are attached to a connector element which is in turn connected to a cystoscope lens port. The treatment and auxiliary tubular members are aligned off-center with respect to the central axis of the obturator so that a cystoscope lens can be inserted in the lens port and pass through the axial center of the obturator. Each auxiliary tubular member receives incident light from a different portion of the remote situs. The apparatus is particularly useful for conducting phototherapy in body cavities and has been demonstrated in the phototherapy treatment of superficial cancer in the bladder.

Method for measuring incident light in a body cavity

A device for measuring incident light in a remote situs such as a body cavity which includes a central tubular member through which light is delivered to the remote situs and one or more auxiliary tubular members through which incident light in the remote situs is transmitted to a light detector. Each auxiliary tubular member receives incident light from a different portion of the remote situs. The apparatus is particularly useful for conducting phototherapy in body cavities and has been demonstrated in the phototherapy treatment of superficial cancer in a bladder.

Device for measuring incident light in a body cavity

A method is disclosed for the treatment of hypercalcemia in a patient, by administering to the patient an effective amount of suramin, or an active analogue thereof, for lowering calcium plasma levels in the patient. Human data shows a single course of treatment lowers plasma calcium levels to normal for three months.

Suramin and active analogues thereof in the treatment of hypercalcemia

Growing community of inventors

Gaithersburg, MD, United States of America

McClellan M Walther